📰 Merck Sharp News
Page 2 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
May 21, 2024
The Pharmaceutical Journal from the Royal Pharmaceutical Society
May 21, 2024
The Slovenia Times is a web portal featuring in-depth news from Slovenia powered by the STA
May 20, 2024
Sweid & Sweid said work has been completed on its latest Grade-A commercial property - 6 Falak - in Dubai Internet City. Spanning 102,000 sq ft, it offers several key amenities including a tranquil private garden and event space for exclusive tenant use.
May 16, 2024
KUALA LUMPUR: The National Cancer Society Malaysia (NCSM) is appealing to the public and corporations for donations to raise RM9 million for an on-gro...
May 7, 2024
ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30...
May 6, 2024
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 -- LAVA Therapeutics N.V. , a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of...
May 4, 2024
Given the Scottish political shenanigans of the past ten days, you could be forgiven for missing a rather exciting developing in cancer research. On…
May 3, 2024
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Cocrystal Pharma (NASDAQ:COCP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Insider & Institutional Ownership 86.2% of Milestone […]
May 3, 2024
Recent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK inhibitors unless there is no other alternative.
May 2, 2024
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational...